Ghostwriters in the sky

September 18th, 2010 by Ben Goldacre in bad science, big pharma, ghostwriters, regulating research | 42 Comments »

Ben Goldacre, The Guardian, Saturday 18 September 2010

If I tell you that Katie Price did not, necessarily, write her own book, this is not a revelation. From academics I have slightly higher expectations, but now the legal system has spat out another skip full of documents: this time, we get a new insight into the strange phenomenon of medical ghost-writing. Read the rest of this entry »

How myths are made

August 8th, 2009 by Ben Goldacre in bad science, big pharma, ghostwriters, publication bias, references, structured data, systematic reviews | 41 Comments »

Ben Goldacre, Saturday 8 August 2009, The Guardian.

Much of what we cover in this column revolves around the idea of a “systematic review”, where the literature is surveyed methodically, following a predetermined protocol, to find all the evidence on a given question. As we saw last week, for example, the Soil Association would rather have the freedom to selectively reference only research which supports their case, rather than the totality of the evidence.

Two disturbing news stories demonstrate how this rejection of best practice can also cut to the core of academia.

Read the rest of this entry »

Elsevier get into fanzines

May 8th, 2009 by Ben Goldacre in academic publishing, bad science, big pharma, ghostwriters | 36 Comments »

Ben Goldacre

The Guardian

Saturday 8 May 2009

In Australia a fascinating court case has been playing out around some people who had heart attacks after taking the Merck drug Vioxx. This medication turned out to increase the risk of heart attacks in people taking it, although that finding was arguably buried in their research, and Merck have paid out more than £2bn to 44,000 people in America, although they deny any fault. British users of the drug have had their application for legal aid rejected, incidentally: health minister Ivan Lewis promised to help them, but FOI documents obtained by The Guardian last week showed that within hours, Merck launched an expensive lobbying effort that convinced him to back off.

Read the rest of this entry »